REGENXBIO Inc. (RGNX)
Develops gene therapies that fix genetic diseases by delivering healthy genes into damaged cells
$9.60-0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+17.2%
The outlook
RGNX is trading near the lower end of its 52-week range, with analyst consensus showing strong "Buy" support and an average price target roughly 153% above the current level. The stock's recent price action is mixed relative to its moving averages, though the overall sentiment leans bullish based on broader technical and sentiment measures.
What’s behind the score
Analyst consensusBuy — 1.5 avg of 11 analysts
Price trendMixed vs its moving averages
52-week range39% of the way from its 52-week low to high
Price targetAvg target +153% vs current price
Analyst price target
~12-month · 11 analysts$24.27average target+152.8% vs now
Now $9.60
Low $10.00High $50.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$614.6M
52-wk high
$16.19
52-wk low
$5.46
50-day avg
$9.15
200-day avg
$10.61
Trailing P/E
—